within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05B_AntivaricoseTherapy.C05BA53_HeparinCombinations;

model HeparinCombinations
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.916666666666667e-07,
    adminDuration = 600,
    adminMass = 5000 / 1000000,
    adminCount = 1,
    Vd = 7.000000000000001e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>HeparinCombinations</td></tr><tr><td>ATC code:</td><td>C05BA53</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>5000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.07</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.015</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Heparin, in combination preparations, is an anticoagulant used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. It acts by potentiating the activity of antithrombin III, thereby inhibiting the formation of fibrin clots. This drug is typically administered parenterally due to poor oral bioavailability and is used in both inpatient and outpatient settings. Heparin combinations may contain local anesthetics or other agents. Heparin and its combinations remain approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult patients receiving heparin combination preparations; no specific publication found for C05BA53 combination products.</p><h4>References</h4><ol><li><p>Bateman, RM, et al., &amp; Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. <i>Critical care (London, England)</i> 20(Suppl 2) 94–None. DOI:<a href=\"https://doi.org/10.1186/s13054-016-1208-6\">10.1186/s13054-016-1208-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27885969/\">https://pubmed.ncbi.nlm.nih.gov/27885969</a></p></li><li><p>Hermiz, J, et al., &amp; Toquica Gahona, C (2025). Apixaban Failure in A Post-Bariatric Surgery Female Patient with Thoracic Aortic Thrombus Secondary to Covid-19. <i>European journal of case reports in internal medicine</i> 12(4) 005254–None. DOI:<a href=\"https://doi.org/10.12890/2025_005254\">10.12890/2025_005254</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40270670/\">https://pubmed.ncbi.nlm.nih.gov/40270670</a></p></li><li><p>Laham, RJ, et al., &amp; Simons, M (1999). Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 27(7) 821–826. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10383927/\">https://pubmed.ncbi.nlm.nih.gov/10383927</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C05BA53 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end HeparinCombinations;
